Last reviewed · How we verify
Monthly Ranibizumab
At a glance
| Generic name | Monthly Ranibizumab |
|---|---|
| Also known as | Ranibizumab |
| Sponsor | Brian Burke, MPH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema (PHASE3)
- A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) (PHASE3)
- Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD (PHASE3)
- Ranibizumab and Reduced Fluence PDT for AMD (PHASE2)
- Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting (NA)
- Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (PHASE3)
- Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab (PHASE4)
- Stereotactic Radiotherapy for Wet AMD (STAR) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Monthly Ranibizumab CI brief — competitive landscape report
- Monthly Ranibizumab updates RSS · CI watch RSS
- Brian Burke, MPH portfolio CI